Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00021
|
|||||
| Drug Name |
Teniposide
|
|||||
| Synonyms |
4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside; Demethyl Epipodophyllotoxin Thenylidine Glucoside; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); PTG; Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; Teniposido; Teniposido [INN-Spanish]; Teniposidum; Teniposidum [INN-Latin]; VM 26; VM-26; VM-26 (TN); Vee M-26; Veham-Sandoz; Vehem; Vumon; Vumon (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11:2B33.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H32O13S
|
|||||
| Canonical SMILES |
COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O
|
|||||
| InChI |
InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
|
|||||
| InChIKey |
NRUKOCRGYNPUPR-QBPJDGROSA-N
|
|||||
| CAS Number |
CAS 29767-20-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 656.7 | Topological Polar Surface Area | 189 | ||
| Heavy Atom Count | 46 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 14 | |||
| XLogP |
1.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10300907
,103589230
,104253379
,104645164
,118046116
,119526326
,124757497
,125164301
,135692278
,136178636
,137001864
,139137932
,140852399
,14912717
,152035492
,162037723
,162174797
,163620769
,163686094
,175267905
,176484801
,178103449
,179116911
,184811965
,187072639
,223384958
,226396002
,241050196
,251887699
,252220258
,252390155
,252401148
,252451125
,49965048
,51063681
,53788607
,57405354
,597750
,7980753
,99030090
,99246079
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Teniposide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.